Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$102.80 USD
-2.21 (-2.10%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $102.78 -0.02 (-0.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMCompany Summary
Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. Ligand has merged with CyDex. By this, it added an antibody-generating platform, OmniAb, to the company's portfolio. Its other technology platforms include antigen discovery platform & protein expression platform. All these technologies have created a strong platform for Ligand to seek new licenses and partnerships. Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Celgene, Gilead & Lilly, etc. The company continues to buy smaller companies to increase its technology platforms.
Company Summary
General Information
Ligand Pharmaceuticals Incorporated
555 HERITAGE DRIVE SUITE 200
JUPITER, FL 33458
Phone: 858-550-7500
Fax: 858-550-1826
Email: investors@ligand.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/13/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.18 |
Current Year EPS Consensus Estimate | 4.71 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/13/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 105.01 |
52 Week High | 112.13 |
52 Week Low | 49.24 |
Beta | 1.01 |
20 Day Moving Average | 104,988.95 |
Target Price Consensus | 131.00 |
4 Week | -0.98 |
12 Week | 22.00 |
YTD | 43.94 |
4 Week | -2.16 |
12 Week | 16.82 |
YTD | 20.40 |
Shares Outstanding (millions) | 18.27 |
Market Capitalization (millions) | 1,878.05 |
Short Ratio | NA |
Last Split Date | 11/19/2010 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 21.83 |
Trailing 12 Months | 22.01 |
PEG Ratio | NA |
vs. Previous Year | -16.36% |
vs. Previous Quarter | 15.00% |
vs. Previous Year | 57.52% |
vs. Previous Quarter | 34.07% |
Price/Book | 2.39 |
Price/Cash Flow | 20.55 |
Price / Sales | 14.07 |
6/30/24 | 7.91 |
3/31/24 | 8.52 |
12/31/23 | 11.98 |
6/30/24 | 6.99 |
3/31/24 | 7.50 |
12/31/23 | 10.27 |
6/30/24 | 16.82 |
3/31/24 | 20.70 |
12/31/23 | 14.15 |
6/30/24 | 15.81 |
3/31/24 | 19.51 |
12/31/23 | 12.72 |
6/30/24 | 43.69 |
3/31/24 | 51.15 |
12/31/23 | 61.10 |
6/30/24 | 29.69 |
3/31/24 | 79.30 |
12/31/23 | 37.80 |
6/30/24 | 39.71 |
3/31/24 | 102.75 |
12/31/23 | 48.48 |
6/30/24 | 43.07 |
3/31/24 | 45.55 |
12/31/23 | 40.39 |
6/30/24 | 0.49 |
3/31/24 | 0.40 |
12/31/23 | 0.47 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |